Item(by='dm319', descendants=None, kids=[25410850], score=None, time=1607893280, title=None, item_type='comment', url=None, parent=25408278, text='The paper is available [1].  They did a reasonable job - 9% black&#x2F;african-american and nearly 30% latino (the trial was run in Argentina and Brazil).  Subgroup analysis similar efficacy between groups.  Around 25% were more than 65.  Maybe not so ideal as that is one of the key groups.  Immunocompromised were excluded, which is understandable, but the data would have been interesting.<p>[1] <a href="https:&#x2F;&#x2F;www.nejm.org&#x2F;doi&#x2F;full&#x2F;10.1056&#x2F;NEJMoa2034577?query=RP" rel="nofollow">https:&#x2F;&#x2F;www.nejm.org&#x2F;doi&#x2F;full&#x2F;10.1056&#x2F;NEJMoa2034577?query=RP</a>')